Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the pricing of an upsized underwritten public offering of 2,808,988 shares of its common stock at a public ...

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these shares, nor shall there be any sale of these shares in any state or jurisdiction in which such ...

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) has been given an average recommendation of “Buy” by the seven ...

Tarsus Pharmaceuticals (NASDAQ:TARS) priced an upsized underwritten public offering of 2.81M shares of its common stock at a public offering price of $44.50 per share. Underwriters have a 30-day ...

U.S. Customs and Border Protection (CBP) has claimed an object that people from Quinlan say fell from the sky on Tuesday ...

The Dakota Cougars defeated the Anchor Bay Tars 52-47 on Wednesday, March 5 to advance to the Division 1 district ...

With a 12-month price target of $56.25/share, TARS stock is a BUY for aggressive growth investors, poised for profitability by 2026. The active ingredient in Xdemvy is a small molecule called ...

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a ...

However, according to the Commonwealth Ombudsman, designated communications providers (DCPs) are receiving duplicated ...